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Rationale: Modulation of the activity of sarcoendoplasmic reticulum
calcium ATPase (SERCA) can profoundly affect Ca21 homeostasis.
Although altered calcium homeostasis is a characteristic of cystic
fibrosis (CF), the role of SERCA is unknown.
Objectives: This study provides a comprehensive investigation of
expression and activity of SERCA in CF airway epithelium. A detailed
study of the mechanisms underlying SERCA changes and its con-
sequences was also undertaken.
Methods: Lung tissue samples (bronchus and bronchiole) from
subjects with and without CF were evaluated by immunohistochem-
istry. Protein and mRNA expression in primary non-CF and CF cells
was determined by Western and Northern blots.
Measurements and Main Results: SERCA2 expression was decreased in
bronchial and bronchiolar epithelia of subjects with CF. SERCA2
expression in lysates of polarized tracheobronchial epithelial cells
from subjects with CF was decreased by 67% as compared with those
from subjects without CF. Several non-CF and CF airway epithelial cell
lines were also probed. SERCA2 expression and activity were consis-
tently decreased in CF cell lines. Adenoviral expression of mutant
F508 cystic fibrosis transmembrane regulator gene (CFTR), inhibition
of CFTR function pharmacologically (CFTRinh172), or stable expres-
sion of antisense oligonucleotides to inhibit CFTR expression caused
decreased SERCA2 expression. In CF cells, SERCA2 interacted with
Bcl-2, leading to its displacement from caveolae-related domains of
endoplasmic reticulum membranes, as demonstrated in sucrose
density gradient centrifugation and immunoprecipitation studies.
Knockdown of SERCA2 using siRNA enhanced epithelial cell death
due to ozone, hydrogen peroxide, and TNF-a.
Conclusions: Reduced SERCA2 expression may alter calcium signaling
and apoptosis in CF. These findings decrease the likelihood of
therapeutic benefit of SERCA inhibition in CF.
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Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis
transmembrane regulator gene (CFTR), an epithelial anion
channel, resulting in the common autosomal recessive disease.
Relentless progressive lung infection and excessive secondary
inflammation remains the principal cause of death in CF. The
most frequent CF-associated mutation, accounting for about 70%
of CF alleles, is deletion of phenylalanine 508 (DF508 CFTR).
DF508 CFTR has reduced chloride channel activity, impaired
processing, and decreased stability at the cell surface. Abnormal
processing leads to its retention in the endoplasmic reticulum
(ER) and rapid intracellular degradation. For these reasons,
DF508 CFTR fails to function as a cAMP-activated Cl2 channel
(1). Previous reports have indicated that sarcoendoplasmic re-
ticulum calcium ATPase (SERCA) inhibitors can decrease
calcium concentrations within the ER and thereby interfere with
the ability of calcium-dependent chaperone proteins to retain
misfolded DF508 CFTR within the ER (2). These investigators
have suggested that blockade of this chaperone interaction by
the use of SERCA inhibitors allows misfolded DF508 CFTR to
escape the ER, reach the cell surface, and function as a Cl2
channel (3). These findings precipitated a remarkable number of
investigations and resulted in several papers, indicating that
SERCA pump inhibitors like curcumin and/or thapsigargin can
(4–9) or cannot (10–13) enhance DF508 CFTR trafficking to the
plasma membrane and apical epithelial chloride transport.
The release of calcium ions from ER regulates essential cellular
functions, including secretion, contraction, gene transcription, and
survival (14). Because SERCA is responsible for (re)loading of ER
calcium after such signaling events, its function can be important at
the level of the whole organ and organism. For example, SERCA2
is the only SERCA isoform expressed in cardiac muscle, and
decreased SERCA2 expression is a key event in congestive heart
failure (15). Its importance is further demonstrated by the lethal
phenotype of SERCA2 knockout mice and the loss of calcium
regulation in cells with only one copy of the SERCA2 gene (16, 17).
In CF, release of ER calcium by activation of purinergic receptors
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Sarcoplasmic/endoplasmic reticulum Ca21-ATPase (SERCA)
inhibitors are being tested to enhance epithelial Cl2 transport;
however, potential beneficial effects are unproven. The status
of SERCA2 expression and activity in cystic fibrosis airway is
unknown.
What This Study Adds to the Field
SERCA2 expression and activity are decreased in cystic
fibrosis airway epithelium, resulting in enhanced suscepti-
bility to oxidants.
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can allow activation of Ca21-activated chloride channels, a princi-
pal, albeit partial, compensatory mechanism for impaired chloride
secretion in CF that could diminish excessive sodium reabsorption
by ENaC (18). Hence, ER Ca21 stores can have direct importance
in the adaptation of CF epithelium.
Despite the abundant research into potential effects of SERCA
inhibitors on DF508 CFTR trafficking and function, the expression
of SERCA isoforms in CF and non-CF airway epithelium has not
been systematically evaluated. Herein, we report that expression of
the principal lung isoform, SERCA2, was consistently down-
regulated in CF airways, primary cultures of polarized CF airway
epithelial cells, in response to genetic or pharmacologic inhibition
of wild-type CFTR expression or function and upon expression
of DF508 CFTR in non-CF epithelium. Even though the low-
affinity SERCA3 isoform was up-regulated, total SERCA activity
was decreased. In CF cells, SERCA2 was associated with Bcl-2 in
ER membranes, and SERCA/Bcl-2 interaction was previously re-
ported to cause inactivation and displacement of SERCA from
membrane microdomains, referred to as caveolae-related domains
(CRDs) (19, 20). Knockdown of SERCA2 using siRNA revealed
that it is required for the survival of airway epithelial cells during
oxidative stress. Not only do these findings indicate additional
reasons why the strategy of SERCA inhibition should not be of
benefit in CF, but they also have potential implications for altered
calcium homeostasis and epithelial cell response in the disease
pathogenesis. Some of the results of these studies have been
previously reported in the form of abstracts (21, 22).
MATERIALS AND METHODS
Cell Culture
Primary human bronchial epithelial cells (HBEs) were obtained from
non-CF and CF lungs under a protocol and consent form approved by the
University of North Carolina School of Medicine Committee on the Pro-
tection of the Rights of Human Subjects. Epithelial cells were removed
from the lower trachea and bronchi by protease XIV digestion, and cells
were plated in bronchial epithelium growth medium on collagen-coated
dishes as described previously (23). Approximately 5 3 105 passage
2 cells were seeded onto 12-mm-diameter type VI collagen (Sigma, St.
Louis, MO)–coated Millicell CM inserts (0.4 mM pore size) (Millipore
Corporation, Bedford, MA) and, after confluence on Days 4 and 5, were
maintained at an air–liquid interface (ALI). Additional primary human
bronchial epithelial cells were isolated in our laboratory from donor
airway tissues obtained from the National Disease Research Inter-
change, with approval of National Jewish Institutional Committee for
the Protection of the Rights of Human Subjects. The airway epithelial
cell lines used were IB3–1 and a ‘‘corrected’’ cystic fibrosis (CF) cell line
that was derived from IB3–1 cells stably transfected with wild-type
CFTR (C-38) (ATCC, Manassas, VA). IB3–1 and C-38 cells were grown
in LHC-8 media (Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum and penicillin/ streptomycin. CFBE41o- (CF41o-) and
CFBE45o- (CF45o-) and a wild-type airway epithelial cell line,
16HBE14o- (16HBEo-), were provided by Prof. D. Gruenert (California
Pacific Medical Center Research Institute, University of California at
San Francisco). These cell lines were cultured in Eagle’s minimal
essential medium (Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum, L-glutamine, and penicillin/streptomycin at 378C
under 5% CO2. 16HBEo- cells with stable expression of sense (16HBE-
S) and antisense CFTR (16HBE-AS) oligonucleotides were cultured as
described previously (24). Minimally transformed primary bronchial
epithelial UNCN3T from the lab of Dr. Randell was also used (25). All
experiments comparing primary non-CF and CF cells were performed
with polarized cultures grown simultaneously and matched for passage
number, the number of cells plated, and days in culture.
Adenoviral Transduction
Transduction of wild-type CFTR, mutated CFTR (DF508), and GFP-
encoding adenoviral vectors was performed as described previously (26).
The vectors (H590.040CMVGFP-CFTR and H590.040CMVGFP-DF508)
were provided by Vector Core at the University of Pennsylvania as
described elsewhere (27). The recombinant viruses were added to the cell
cultures (multiplicity of infection, 10:1) on Day 3 for 17 hours. The
transduction efficiency was estimated by observing green fluorescence of
adenoviral GFP-transduced cells.
SERCA2 Gene Silencing Using siRNA
Predesigned human ‘SMARTPOOL’ SERCA2 siRNAs were purchased
from Dharmacon (Lafayette, CO). Primary airway epithelial cells not at
ALI were transfected with 50 nM siRNA using DharmaFECT2 siRNA
transfection reagent (Dharmacon) according to the manufacturer’s
instructions. Silencer negative control siRNA was used as a nonspecific
siRNA, and mock transfection was used as a negative control. Trans-
fection of siRNA in primary human airway epithelial cells has previously
been described (28).
Statistical Analysis
All statistical calculations were performed with JMP and SAS software
(SAS Institute, Cary, NC). Means were compared by two-tailed t test for
comparison between two groups or one-way analysis of variance fol-
lowed by the Tukey-Kramer test for multiple comparisons for analyses
involving three or more groups. P , 0.05 was considered significant.
RESULTS
Expression of SERCA2 in CF Airway Cell Lines
SERCA2 expression was determined by Western blot in non-CF
and CF cell lysates. Expression of SERCA2 protein was de-
creased in two CF cell lines (CF41o- and CF45o-) as compared
Figure 1. Sarcoplasmic/endoplasmic reticulum Ca21-ATPase (SERCA)2
protein and RNA expression in non-cystic fibrosis (CF) and CF cell lines.
Lysates from cultures of 16HBEo-, CF41o-, and CF45o- cells were
analyzed for SERCA2 protein and RNA expression using Western and
Northern blot as indicated in METHODS. (A and B) Representative Western
(experiments repeated six times) and Northern blots (experiments
repeated three times) are shown, respectively. To localize SERCA2, cells
grown on glass coverslips were fixed and coimmunostained for SERCA2
(red) and the endoplasmic reticulum (ER)-specific protein protein disul-
phide isomerase (PDI, green) (C). The figure represents one data set from
an experiment performed in duplicate. The individual experiment was
repeated three times.
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with the non-CF 16HBEo- cells (Figure 1A). Quantitation of
SERCA2/b-actin intensity yielded 3.51 6 0.27, 1.76 6 0.23, and
2.59 6 0.29 arbitrary units for 16HBEo-, CF41o-, and CF45o-
cells, respectively. A statistically significant decrease in SERCA2
protein was observed in IB3–1 cells versus C-38 cells (0.22 6 0.02
vs. 1.24 6 0.01 SERCA2/b-actin intensity units, respectively;
figure not shown) and in JME/CF15 versus Calu-3 cells (0.38 6
0.01 vs. 0.62 6 0.01 SERCA2/b-actin intensity units, respectively;
figure not shown). Decreased SERCA2 mRNA was also ob-
served (Figure 1B) in CF41o- and CF45o- cells relative to that
found in non-CF 16HBEo- cells.
Experiments were also performed to immunolocalize
SERCA2. The results indicated diminished SERCA2 expression
in CF cells relative to non-CF cells (Figure 1C). In non-CF cells,
SERCA2 was located in ER, as demonstrated by the enhanced
‘‘merged’’ staining for the ER marker protein disulfide isomerase
(PDI) and SERCA2 in these cells, whereas CF cells demonstrated
decreased overall SERCA2 staining intensity, preservation of ER
staining for PDI, and diminished merged signal for PDI and
SERCA2 co-staining.
ER Density and SERCA2 Protein and Activity in CF Cells and
Their Microsomal Fractions
The decreased expression of SERCA2 in CF cells was not caused
by diminished ER mass in these cells. ER density was quantified
Figure 2. Estimation of endoplasmic reticulum (ER) content (A) and
sarcoplasmic/endoplasmic reticulum Ca21-ATPase (SERCA2) (protein
and activity) in purified microsomal membranes (B). Live cells cultured
in chambered coverglass were stained using ER-Tracker Blue-White
DPX (Molecular Probes) (A). The lower panel shows the quantification
of fluorescence intensity per whole cell area. For each of three cell lines,
about 20 cells were analyzed. Results show means of the data.
*Significant difference (P , 0.05) from non-cystic fibrosis (CF) 16HBEo-
cells (n 5 3). (B, top panel) Representative result of SERCA2 expression
in purified microsomal membranes of 16HBEo- (lane 1), CF41o- (lane
2), and CF45o- (lane 3) cells. Microsomal extracts (20 mg) were loaded
on 7.5% polyacrylamide gel, and Western blot analysis was performed
for SERCA2 expression. (B, lower panel) Thapsigargin (2 mM)-sensitive
Ca21ATPase activity in microsomal membranes of normal and CF cells.
*Significant difference from 16HBEo- cells (P , 0.05) (n 5 3; represents
three individual experiments).
Figure 3. Sarcoplasmic/endoplasmic reticulum Ca21-ATPase (SERCA2)
expression in air–liquid interface (ALI), 17–42 days of cultures of
primary non-cystic fibrosis (CF) and CF airway epithelial cells. (A)
Representative images of in situ immunohistochemistry for SERCA2
expression in cultures fixed with 4% paraformaldehyde (PFA) and
stained with 3,3-diaminobenzidine and H2O2 for detection of horeser-
adish peroxidase–coupled mouse secondary antibody. Data shown are
from cells from four individual (1–4) non-CF donors and four individual
(5–8) CF donors (one of three separate experiments). Identical staining
conditions were used for staining non-CF and CF sections. For Western
blot, lysates from the ALI cultures of the cells from the above donors
were analyzed by SDS PAGE on 4 to 15% gradient gels, and the
proteins were transferred electrophoretically onto nitrocellulose mem-
branes. The membranes were probed with the SERCA2 antibodies at
a 1/1,000 dilution (B). (C) Quantification of Western blots for SERCA2
expression in ALI cultures of cells from non-CF and CF donors (14 non-
CF and 8 CF) analyzed in three separate experiments. The mean of the
non-CF group is the control value; . 60% of CF donors were F508
double mutant, and z 90% had F508 mutation for one allele in the
CFTR gene. The bars represent means of data. * Significant difference
(P , 0.05) from non-CF cells (results of three individual experiments).
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in CF and non-CF cell lines using an ER-specific fluorescent dye
(ER-Tracker Blue-White DPX; Molecular Probes, Carlsbad,
CA) (Figure 2A, upper panel). Similar to what was seen with
PDI staining, CF cell cultures showed similar or greater ER
staining intensity with the fluorescent dye. Specifically, CF45o-
cells had significantly greater staining intensity than 16HBEo-
cells, and CF41o- cells showed a similar, nonsignificant trend
(Figure 2A, lower panel). These findings are consistent with
previous reports of increased apical ER density in CF cells (29).
In microsomal membrane (ER) preparations, CF cell lines
CF41o- and CF45o- had decreased SERCA2 protein expression
in absolute terms and per b-actin protein expressed relative to
non-CF cell line 16HBEo- (Figure 2B, upper panel). In these
microsomal membrane preparations, total thapsigargin-inhibitable
Ca21ATPase (SERCA) activity was decreased by approximately
50% in the two CF cell lines relative to the non-CF cells (Figure
2B, lower panel). Because thapsigargin is a specific inhibitor of
SERCA, these findings indicate that diminished SERCA2 ex-
pression resulted in a substantial overall decrease of SERCA
activity in CF cells.
SERCA2 Expression in Primary Polarized Non-CF and CF
Airway Epithelial Cells
SERCA2 expression also was estimated in ALI cultures of
differentiated primary non-CF (14 donors) and CF (eight donors)
cells using immunohistochemistry and Western blot analysis.
Using either technique, expression of SERCA2 in epithelial cells
varied from donor to donor (demographics provided in Table E1
in the online supplement), despite comparable passage number and
days in culture (Figures 3A and 3B). However, mean SERCA2
protein expression (Western blot) was decreased by 67% in
airway epithelial cells from CF donors relative to non-CF (Figure
3C). We also analyzed SERCA2 expression at 7 days of culture,
a stage at which cells are undifferentiated, and at 30 days of cul-
ture, at which time cells are more differentiated (30), in primary
non-CF and CF airway epithelial cells from four different donors
to determine if the extent of differentiation could affect SERCA2
expression. CF airway epithelial cells had decreased SERCA2
expression at 7 days and at 30 days of culture as compared with non-
CF cells (data not shown). Thus, SERCA2 protein expression in
primary polarized CF airway epithelial cells differed from the non-
CF cells to a similar extent as seen in CF versus non-CF cell lines.
SERCA2 Expression in Proximal and Distal Airways from
Human CF and Non-CF Lungs
Immunohistochemistry was used to estimate SERCA2 expres-
sion in lung tissue from subjects with and without CF. SERCA2
staining was predominantly localized to airway epithelium and to
smooth muscle cells in airway and arterial/arteriolar walls.
SERCA2 staining was decreased in bronchial and bronchiolar
epithelium of subjects with CF compared with subjects without
CF (Figures 4A–4D). CF airway epithelium also differed from
non-CF airway epithelium in that the extent of mucus cell
hyperplasia was greater in the former than in the latter. Quanti-
tation of SERCA2 staining (excluding the mucus-containing
regions) revealed a significant decrease in bronchial and bron-
chiolar epithelium of subjects with CF compared with subjects
without CF (Figures 4E and 4F). The demographics of the indivi-
duals with and without CF are provided in Table E2.
SERCA3 expression in CF and non-CF airway epithelial cells
and cell lines SERCA3 is the only other known SERCA isoform
expressed in lung. It differs from SERCA2 in that it has a low
affinity for calcium. By contrast to SERCA2, SERCA3 protein
expression was increased in both CF cell lines, CF41o- and CF45o-,
relative to that seen in the non-CF cell line 16HBEo- (Figure 5A).
Steady-state SERCA3 mRNA expression was not consistently
elevated in CF cell lines, being elevated in CF45o- but not in
CF41o- relative to 16HBEo- (Figure 5B). However, SERCA3
protein expression was increased in primary polarized airway
epithelial cells from CF versus non-CF donors (Figure 5C). These
findings suggest a compensatory response of SERCA3 expression
to the down-regulation of SERCA2 in CF.
Figure 4. Sarcoplasmic/endoplasmic reticulum Ca21-
ATPase (SERCA2) expression in the epithelium of proximal
and distal cystic fibrosis (CF) and non-CF airways. Immu-
nohistochemical localization of SERCA2 was performed as
described in METHODS using identical conditions for non-CF
and CF tissue. Left panel: Nonspecific IgG control. Right
panel: SERCA2 staining in epithelium (arrowheads). SERCA2
staining was found predominantly in the epithelium of non-
CF bronchi (n 5 5 donors) (A) and bronchioles (C), and it
was significantly less intense in the epithelium of CF airways
(n 5 5 donors) (B and D). (E) Quantitation of SERCA2
staining (SERCA2-IgG) in the non-CF and CF bronchi. The
regions containing mucus were excluded during quantita-
tion. For each tissue, two SERCA2 and two IgG-stained
sections were analyzed, and 10 nonmucus areas per section
were randomly selected for quantitation using Image-Pro
Plus version 4.0 (Media Cybernetics, Silver Spring, MD).
Similarly, SERCA2 staining in the non-CF and CF bron-
chioles was quantified (F).
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SERCA2 Protein Expression Is Decreased by Pharmacologic
Inhibition of CFTR Function
To investigate the role of CFTR function in mediating SERCA2
expression, we used the specific CFTR inhibitor CFTRinh172.
Relatively short-term (24-hour) incubation of primary HBE
(ALI; Figure 6A) and the wt-CFTR–corrected C-38 (Figure
6C) cells with CFTRinh172 (20 mM) caused a significant decrease
in SERCA2 protein levels. By contrast, incubation of the parent
CF cell line IB3–1 with the same concentration of the inhibitor did
not cause a further decrease in its expression of SERCA2 (Figure
6C). Exposure of these cells to the inhibitor for this duration did
not cause cytotoxicity.
SERCA2 Protein Expression Is Decreased by Genetic
Inhibition of CFTR Function
The effect of interference with CFTR function was evaluated by
an additional specific genetic approach. SERCA2 expression
was measured in 16HBEo- cells with stable expression of sense
(16HBE-S) and antisense CFTR (16HBE-AS) oligonucleotides
and grown at ALI. cAMP-dependent chloride conductance
was absent in antisense CFTR oligonucleotides (16HBE-AS)-
containing cells (Figure E1A). SERCA2 protein, corrected for
b-actin expression, was diminished in CFTR antisense-express-
ing cells by about two thirds relative to sense-expressing cells
(Figure 7A), comparable to the extent of reduction of SERCA2
expression in primary CF relative to non-CF airway cells.
SERCA2 Protein Expression Is Decreased by Expression of
Mutant DF508 CFTR
The DF508 CFTR mutation causes diminished channel activity,
impaired processing, and reduced CFTR protein stability at the
cell surface. In addition, this mutation inhibits gating of CFTR
channels, resulting in a diminished rate of opening (31). Because
this is the most common CFTR mutation, we sought to determine
the effect of its overexpression in airway epithelial cells on
SERCA2 expression. We conducted studies in minimally trans-
formed primary human bronchial epithelial cells (UNCN3T)
transiently transduced using adenoviral vectors. Compared with
nontransduced, LacZ-overexpressing, and wt-CFTR–overexpress-
ing cells (increased CFTR expression by Ad.wt-CFTR is shown by
Western blot in Figure E1B), DF508 CFTR-overexpressing cells
had decreased SERCA2 protein expression (Figure 7B). Taken
together, the results from use of these three strategies for CFTR
functional inhibition demonstrate a link between diminished
CFTR function and SERCA2 expression.
Bcl-2–induced displacement of SERCA2 from CRDs in CF
cells. Interaction of Bcl-2 with SERCA2 has been described
previously (20, 32). Bcl-2 binds to and inactivates SERCA and
causes SERCA displacement from the CRDs of the ER mem-
brane (19, 20). Sucrose density gradient fractionation of purified
microsomes from non-CF 16HBEo- cells and CF45o- cells was
performed to localize SERCA2 in the CRDs. For the detection of
Figure 5. Expression of low-affinity sarcoendoplasmic reticulum cal-
cium ATPase (SERCA) isoform SERCA3 in cystic fibrosis (CF) and non-CF
airway epithelial cells. (A) Western blot for SERCA3 from whole cell
lysates (20 mg of protein/lane) from non-CF and CF bronchial airway
epithelial cell lines. Membranes were also probed for b-actin to verify
equal loading of protein. (B) Northern blot for SERCA3 mRNA expres-
sion. About 15 mg of RNA was subjected to Northern blot analysis, and
SERCA3 was identified using 32P-labeled cDNA probe. Before hybrid-
ization membranes were analyzed with ultraviolet light exposure for
visualization of 18S and 28S RNA bands to verify equality of RNA
loading and transfer. Equal loading was further established by 28S RNA
(bottom panel) analysis. Cell lysates from air-liquid interface cultures of
primary airway epithelial cells from three non-CF (1–3) and three CF
(4–6) subjects were also assessed for SERCA3 expression by Western
blot (C). Results represent three individual experiments.
Figure 6. Effect of cystic fibro-
sis transmembrane regulator




bronchial epithelial cells were
cultured for short-term duration
on collagen-coated inserts and
then treated with 20 mM
CFTRinh172 for 24 hours. Cell
lysates were prepared, and
Western blot analysis was per-
formed (20 mg protein loaded).
(A) SERCA2 expression in
CFTRinh172–treated primary
bronchial epithelial cells (lanes
1–3 are untreated control; lanes 4–6 are CFTRinh172–treated cells). (B) Quantitative data for SERCA2 expression with and without CFTRinh172 treatment.
The bars represent means of data. *Significant difference (P , 0.05) from non-CF cells (results of three individual experiments are shown). (C)
Representative blot showing the effect of CFTRinh172 on SERCA2 expression treatment in CF IB3–1 cells and CFTR-corrected C-38 cells. (D) Quantitative
data. Bars represent means of data. *Significant difference (P , 0.05) from untreated cells; n 5 3 (experiment repeated twice).
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SERCA2 distribution in the sucrose density fractions, each fraction
was loaded onto the gel for Western blot analysis (Figure 8A).
Fractions were collected from the top of the gradient, where
fraction 1 represents the initial CRD fraction. SERCA2 of
16HBEo- cells primarily localized in the CRD fraction, whereas
the major SERCA2 band of CF45o- cells migrated deeper into the
gradient. Thus, sucrose density gradient centrifugation of micro-
somes from CF preparations showed that SERCA2 was predom-
inantly recovered in fraction 2, whereas non-CF samples showed
SERCA2 predominantly in fraction 1. SERCA2 coimmunopreci-
pitated with Bcl-2 in 16HBEo- and CF45o- cells (Figure 8B).
However, an increased amount of Bcl-2 was detected in CRDs and
the immunoprecipitates from CF cell microsomes. These figures
indicate the presence of increased Bcl-2 expression and Bcl-2–
SERCA2 complexes in CF. The increase in Bcl-2–SERCA2
complexes in CF cells occurred despite the fact that SERCA2
protein was decreased by about 50% in the CF cell line. These
findings indicate a mechanism for decline in ER-associated
SERCA2 expression and total SERCA activity due to Bcl-2
association.
Increased Bcl-2 expression in cellular compartments of CF
cells. We have shown that Bcl-2 was present at higher levels in the
microsomal Bcl-2 immunoprecipitates of CF45o- cells relative to
those present in the non-CF cell line (Figure 8C). Figure 9A shows
the Western blot analysis of Bcl-2 distribution in the nucleus, ER,
and mitochondria of 16HBEo-, CF41o-, and CF45o- cells. In-
creased Bcl-2 protein was observed in each of these cellular
compartments of the two CF, relative to the non-CF, cell lines.
Analysis of total Bcl-2 content in the ER membrane (M) of
16HBEo- and CF45o- cells using ELISA (Table 1) confirmed
findings obtained by Western blot. Bcl-2 contents of whole cell
lysates from differentiated primary human non-CF and CF
bronchial epithelial cells showed a pattern of increase in CF cells,
but the difference was not significantly different (Table 1).
Role of diminished CFTR expression in increased Bcl-2
expression. To determine if decreased CFTR function plays a role
in the enhanced expression of Bcl-2, we isolated ER microsomes
from 16HBEo- cell line stably transfected with sense (S) and
antisense (AS) CFTR oligonucleotide. Increased expression of
Bcl-2 was observed in cells in which CFTR was decreased by
expression of antisense CFTR oligonucleotides (Figure 9B). This
indicates that deficient CFTR expression is sufficient to increase
Bcl-2 expression. Bcl-2 analysis was also performed in lysates
obtained from control and adenovirally transduced primary
human bronchial epithelial cells using ELISA. Cells expressing
DF508 CFTR showed an approximately 2-fold increase in Bcl-2
expression as compared with the control cells (Figure 9C). Direct
and/or indirect effects of altered CFTR function may lead to
persistent endogenous activation of NF-kB in CF airway epithe-
lial cells (33, 34). NF-kB regulates the transcription of Bcl-2 (35,
36). We determined Bcl-2 content and NF-kB activation (by
measuring nuclear p65) of control and TNF-treated primary HBE
cells that were adenovirally transduced with DF508 CFTR
(Figure E2A). There was no change in CFTR expression with
and without TNF treatment in the lacZ, wtCFTR, and DF508
CFTR-expressing cells. The nuclear lysates, when assessed by
Figure 7. Effect of inhibiting functional cystic fibrosis transmembrane
regulator gene (CFTR) expression by antisense CFTR oligonucleotides
(A) or by overexpressing mutated CFTR (B) on sarcoendoplasmic
reticulum Ca21-ATPase (SERCA)2 expression. Cell lysates were pre-
pared from polarized cultures of 16HBEo- cell line stably transfected
with sense (S) and antisense (AS) CFTR oligonucleotide and analyzed
for SERCA2 expression by Western blot. The bars represent means of
data. *Significant difference (P , 0.05) from control (16HBE-S) cells.
The experiment was repeated four times. (B) Results of SERCA2
expression analysis in lysates obtained from control and adenovirally
transduced minimally transformed primary human bronchial epithelial
cells (UNCN3T) grown on collagen-coated culture dishes. The bars
represent means of data. *Significant difference (P , 0.05) from control
(LacZ) cells. The experiment was repeated three times (n 5 3 per
condition).
Figure 8. Translocation of sarcoendoplasmic reticulum Ca21-ATPase
(SERCA2) within caveolae-related domains (CRDs) from the estimation
of endoplasmic reticulum (ER) of cystic fibrosis (CF) cells. Purified
microsomes from 16HBEo- and CF45o- cells were lysed in ice-cold 0.5 M
sodium carbonate buffer. The homogenate was adjusted to 45% (w/v)
sucrose by the addition of 90% sucrose in the MBS buffer and placed in
the bottom of an ultracentrifuge tube. A discontinuous sucrose gradient
was established by overlaying this solution with 4 ml of 38% sucrose and
3 ml of 5% sucrose. The tubes were then centrifuged at 48C for 16 to 18
hours at 130,000 3 g, and fractions were manually collected from the
top of the gradient. To determine the distribution of CRD-associated
proteins within the gradient, each fraction was analyzed by SDS-PAGE,
followed by Western blot analysis with SERCA2 and caveolin antibody
(A). The Western blot shown is representative of findings in three sep-
arate sucrose gradient centrifugation/Western blot experiments. (B and C)
Western blot of SERCA2 and Bcl-2 using immunoprecipitate of micro-
somal fractions from (1) 16HBEo- and (2) CF45o- using Bcl-2 antibody.
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Western blot, showed increased p65 in the DF508 CFTR-express-
ing cells in both conditions of DF508 CFTR, with or without TNF
treatment. Quantitative estimation of p65 in the nuclear lysates
using ELISA revealed statistically significant increased nuclear
p65 upon TNF treatment in the adenoviral lacZ and wtCFTR
transduced cells (Figure E2B). The DF508 CFTR-expressing cells
had increased basal nuclear p65 that was further enhanced upon
TNF treatment. The cells that had increased nuclear p65 had
increased Bcl-2 expression (Figure E2C).
SERCA2 is required for cell survival in oxidative stress. CF
airway epithelial cells are continuously exposed to oxidative
stress presented directly or indirectly by air pollutants, bacte-
rial endotoxins, proinflammatory cytokines, and neutrophils.
For this reason, we sought to determine the potential impact
of diminished SERCA2 expression on airway epithelial cell
survival during challenge by three relevant prooxidant stimuli:
ozone (O3), hydrogen peroxide (H2O2), and TNF-a. SERCA2
siRNA was used to investigate the effect of SERCA2 expres-
sion on O3–induced cell death in primary airway epithelial
cells cultured on collagen coated 6-well plates. First, we
verified that SERCA2 protein levels were reduced in the cells
expressing SERCA2 siRNA (Figure 10A). Transfection with
nonspecific siRNA had no effect on SERCA2 protein expres-
sion, whereas SERCA2 siRNA–treated cells had SERCA2
protein expression decreased by 67% relative to nonspecific
siRNA-treated control cells. Bcl-2 expression was not affected
by SERCA2 knockdown in these cells (data not shown).
Increased apoptotic and necrotic cell death was observed in
the control siRNA-transfected cells upon exposure to 200 ppb
O3 for 18 hours (Figure 10B). SERCA2 siRNA increased
apoptotic and necrotic cell death induced by O3 (25.0 6 7.0%
vs. 42.0 6 3.0% apoptotic cell death in control siRNA vs.
SERCA2 siRNA–expressing cells). Besides O3 as an environ-
mental factor, we assessed the toxicity of TNF-a and H2O2
because these are abundant in CF lungs. With 10 ng/ml TNF-
a, a concentration close to those found in CF airways (37),
there was enhanced cell death in SERCA2 siRNA–expressing
cells, but the extent of death was minimal (4.17 6 0.30% in
control vs. 7.15 6 0.50% total cell death in SERCA2 siRNA–
expressing cells). However, when TNF-a was combined with
IL-1b, another cytokine abundant in CF airways, there was
increased apoptotic cell death in control and 1.7-fold still
greater apoptosis in SERCA2 siRNA–treated cells (Table 2).
The extent of necrosis was not different in the two groups.
Similarly, treatment with H2O2 caused enhanced apoptotic
and necrotic cell death in SERCA2 siRNA–expressing
cells when compared with those expressing control siRNA
(Table 2).
DISCUSSION
Our study on the expression of SERCA2 in CF airways relative to
expression in respiratory cells and tissues of non-CF individuals
reveals that SERCA2 protein expression is decreased in CF
airway epithelial cell lines and primary polarized airway epithe-
lial cells grown at ALI and in vivo in distal and proximal airway
epithelial tissue of subjects with CF. CFTR dysfunction-induced
enhanced NF-kB activation and increased Bcl-2, which interacted
with SERCA2 to translocate it from the caveolae-related
domains (CRDs), were potential mechanisms causing decreased
SERCA2 expression.
In the series of experiments involving primary cells grown at
ALI, although there was considerable variability in expression
from donor to donor, the overall extent of SERCA2 protein
expression was diminished in primary CF cells. Individual vari-
ability in the primary cells could have resulted from variations in
genotype, types of differentiated cells present (e.g., mucus, ciliated),
the types and/or severity of infection(s) previously present, the
presence of additional disease states (e.g., diabetes) in the donor
(38), and/or the types of medications previously administered
(39). SERCA2 protein expression was quantitatively diminished,
as detected by immunohistochemistry, in epithelial cells of large
and smaller airways in lungs of patients with CF. This supports the
potential clinical relevance of these findings. Previous studies
indicated that altered calcium homeostasis in airway epithelial
cells of patients with CF is mainly a result of inflammation and
infection (40, 41). The airway epithelial cell lines used in the
present studies were maintained in the absence of infection and
inflammation for months to years, and the primary cells examined
were cultured in the absence of infection and inflammatory cells
for 1 to 6 weeks. Despite the differences in cell environment,
Figure 9. Increased Bcl-2 expression in the cellular compartments of
cystic fibrosis (CF) cells. Nuclear, endoplasmic reticulum (ER), and
mitochondrial fractions were prepared from (1) 16HBEo-, (2) CF41o-,
and (3) CF45o- cells. Western blots were performed using antibodies
against Bcl-2, cytochrome c oxidase (mitochondrial marker), protein
disulphide isomerase (PDI, ER-specific protein) and lamin C (nuclear
marker) (A). (B) Bcl-2 expression in the ER fraction of 16HBEo- cell line
stably transfected with sense (S) and antisense (AS) CFTR oligonucle-
otide. (C) Total Bcl-2 content in cellular lysates of control and
adenovirally transduced primary human bronchial epithelial cells
grown on collagen-coated culture dishes. The bars represent means
of data of two individual experiments (n 5 4). *Significant difference
(P , 0.05) from control.
TABLE 1. TOTAL BCL-2 EXPRESSION IN NON–CYSTIC FIBROSIS
AND CYSTIC FIBROSIS BRONCHIAL EPITHELIAL CELLS
Cells Total Bcl-2 (ng/mg protein)
Differentiated primary non-CF bronchial
epithelial cells (WCL) (n 5 5 donors)
7.74 6 1.41
Differentiated primary non-CF bronchial
epithelial cells (WCL) (n 5 4 donors)
10.55 6 1.50
16HBEo- (M) 8.90 6 0.11
CF45o- (M) 14.50 6 0.12*
Definition of abbreviations: CF 5 cystic fibrosis; M 5 microsomal membrane
preparations; WCL 5 whole cell lysate.
* Significant difference from non–cystic fibrosis 16HBEo- cells (P , 0.05).
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decreased SERCA2 expression was a constant feature of CF
airway epithelium, suggesting that it is an intrinsic feature of the
disease. This is further supported by IHC studies using lung
tissues of patients with CF. These tissue samples were not free of
infection and chronic inflammation.
ER plays an important role in CF disease pathogenesis. The
decreased SERCA2 expression was not due to a diminished ER
mass in CF cells. In fact, as indicated by staining for the ER-
specific protein PDI and an ER-specific fluorescent dye, CF
airway epithelial cells contained similar or greater quantities of
ER. These findings are generally in agreement with previous
reports of expanded ER in CF (40). Although abnormal DF508
CFTR can be retained and degraded in ER, and transient
adenoviral overexpression of DF508 CFTR was sufficient to
cause decreased SERCA2 expression in non-CF airway epithelial
cells, the findings in our study (e.g., antisense CFTR oligonucle-
otide expression) do not indicate that the presence of mutant
CFTR(s) in the ER is the principal cause of diminished SERCA2
expression in CF airway epithelial cells.
Recent investigations on the modulation of SERCA2 activity
have reported the presence of an important interaction between
SERCA2 and Bcl-2, resulting in SERCA2’s translocation from
CRD to membrane domains of higher density, partial unfolding,
and inactivation (19, 20). Bcl-2 is capable of interaction with
SERCA1 or SERCA2. In purified sarcoplasmic reticulum pre-
parations, the addition of Bcl-2 causes significant loss of SERCA
activity (20). Because of relevant reports in CF (42, 43), we de-
termined if such an interaction occurs in CF airway epithelium.
Bcl-2 protein expression and association with SERCA2 was
elevated in CF relative to non-CF airway epithelial cells. Given
that Bcl-2 binding to SERCA2 in other tissues can displace it
from CRD and inactivate it, our findings suggest that similar
mechanisms could act in lung epithelium to diminish SERCA2
protein expression and activity in the ER. We do not know
whether SERCA2 is also chemically modified such that its
interaction with Bcl-2 and/or its inactivation is enhanced.
A previous study in relation to CF and Bcl-2 expression
indicated that Bcl-2 expression increased mucus cell metaplasia
of airway epithelial cells and that insufflation of bacterial
endotoxin could cause such changes in the airways of rats
(42). Our studies of CF and non-CF airway epithelial cell lines
and of CFTR sense and antisense oligonucleotide-expressing
cells were done in the absence of bacterial infection, inflamma-
tion, and endotoxin, and these cells were maintained in the
absence of these factors for extended periods of time. In
addition, the cells in these experiments were not cultured at
ALI. Thus, unlike our studies of primary cell cultures grown at
ALI, they could not undergo differentiation to mucus-express-
ing cells and could not have had altered Bcl-2 expression in
association with mucus cell differentiation. In this case, such
culture conditions were considered advantageous because they
prevented potential Bcl-2 changes due to differentiated pheno-
type. Some variability in SERCA2 expression in CF primary
airway epithelial cells from different donors could have related
to differences in mucus cell differentiation of such cultures, but
this could not have occurred in the various transformed CF and
non-CF cell lines we studied. Based on the absence of infection,
inflammation, bacterial endotoxin, and mucus cell differentia-
tion in our experiments pertinent to Bcl-2, our findings indicate
that increased Bcl-2 expression is an inherent feature of CF
airways epithelium.
CFTR dysfunction is associated with aberrations in a number
of signaling pathways, including those related to inflammation
and infection. The specific link(s) between CFTR dysfunction
and increased NF-kB activation in CF cells remains undefined.
However, there are several factors that could cause this to occur
(43). Our experiment with overexpression of mutant CFTR
provides further evidence that CFTR dysfunction causes in-
creased NF-kB activation p65 mobilization to the nucleus. In-
creased NF-kB–mediated proinflammatory gene transcription
has been reported elsewhere (24) in the cells expressing CFTR
antisense oligonucleotide (16HBE-AS), which is another model
we studied. NF-kB is a transcriptional regulator of Bcl-2 and
other proteins of the Bcl-2 family (35, 44). Thus, increased Bcl-2
in cells with CFTR dysfunction could result, at least in part, from
enhanced NF-kB activation.
Increased expression of Bcl-2 in CF airway epithelium could
have beneficial and/or detrimental effects. It could increase
proliferation and diminish cell death via its antiapoptotic action.
Increased proliferation in the submucosal gland and in basal cells
of CF airways has been described elsewhere (45), and this could
have an important role in airway epithelial regeneration and
Figure 10. Sarcoendoplasmic reticulum Ca21-ATPase (SERCA2) is
essential for cell survival during oxidative stress. (A) SERCA2 knockdown
using SERCA2 siRNA. Top: representative Western blot of SERCA2
expression in primary human bronchial epithelial cells (grown on
collagen-coated culture dishes) (1) mock-transfected or transfected
with (2) control or (3) SERCA2 siRNA. Bottom: Quantitation of SERCA2
knockdown. The bars represent means of data. *Significant difference
(P , 0.05) from control siRNA-transfected cells (n 5 3; three individual
experiments). For assessing ozone toxicity, primary human airway
epithelial cells were transfected either with a control or SERCA2 siRNA
for 24 hours and exposed to 0 ppb or 200 ppb ozone for 18 hours.
After exposure, cells were analyzed for cell death using Vybrant
apoptosis assay kit. The Alexa Fluor-488–labeled annexin-positive
apoptotic and Sytox green-positive dead cells were quantified by flow
cytometry (B). The columns represent means of data. *Significant
difference (P , 0.05) from 0 ppb control cells. #Significant difference
from 200 ppb control cells (n 5 3). This experiment was repeated four
times.
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repair. Furthermore, osmotic challenges routinely faced by CF
airway epithelial cells might be better tolerated in the presence of
Bcl-2 overexpression. CF epithelial cells have increased suscep-
tibility to osmotic stress and blunted regulatory volume decrease
responses (46, 47), and Bcl-2 overexpression can stimulate such
responses and promote survival (48). Moreover, by inhibiting
apoptosis in the presence of oxidative stress and/or infection, Bcl-
2 expression at high levels could favor necrosis of airway
epithelium and enhance the release of cell contents like DNA
and proteolytic enzymes, worsening airways damage and ob-
struction. Such effects of Bcl-2 may be site specific. In this context
and in the context of the present study, it is noteworthy that others
recently described a paradoxical proapoptotic effect of high-level
Bcl-2 expression when Bcl-2 is localized to the nucleus (49).
Although Bcl-2 expression often acts to oppose apoptosis and cell
death, it might do otherwise in the context of CF, if, for example,
its effects on SERCA2 secondarily alter other functions, like
alternate chloride channels, that could themselves influence cell
fate.
Members of the Bcl-2 family regulate ER Ca21 homeostasis.
Bcl-x(L) binds to the inositol trisphosphate receptor (InsP(3)R)
Ca21 release channel to enhance Ca21 release, resulting in
reduced ER [Ca21], increased oscillations of cytoplasmic Ca21
concentration ([Ca21]i), and resistance to apoptosis (50). Bcl-2
also increases emptying of endoplasmic reticulum Ca21 stores
during photodynamic therapy–induced apoptosis (51). Emptying
of ER stores after SERCA inhibition with thapsigargin causes
cells to undergo growth arrest or apoptotic cell death (52). Thus,
Bcl-2 and Bcl-2–related proteins regulate apoptosis by altering
ER [Ca21] via modulation of InsP(3)R and/or SERCAs (20, 53).
However, it is not clear whether reduced ER [Ca21] or enhanced
[Ca21]i signaling is most relevant for apoptosis protection.
Although the literature is mixed on the ability of CF cells to
undergo apoptosis, recent reports indicated that CF airway
epithelial cells are more prone to apoptosis and/or necrosis
than non-CF cells (54, 55). Despite the antiapoptotic effects
that Bcl-2 could have in the CF airway, we sought to define
whether down-regulation of SERCA2 in airway epithelial cells,
whether via Bcl-2 or other mechanisms, affects cell survival
there. We specifically asked whether diminished SERCA2
expression could enhance apoptosis and/or cell death. Primary
airway epithelial cells expressing SERCA2 siRNA showed
enhanced toxicity to three different stimuli, each of which
can contribute, directly and indirectly, to oxidative stress in CF
airways (56). These included O3, H2O2, and TNF-a 1 IL-1b.
These studies indicated the capacity of SERCA2 down-regula-
tion to modulate susceptibility to cell death due to oxidative
stress.
There are multiple examples in the cardiovascular literature
in which SERCA modification can potentially affect the
disease process. Oxidative stress may modify SERCA struc-
ture and/or function (57). In CF airways, oxidative stress may
be innate and/or secondary to inflammation. Cholesterol also
can affect SERCA expression (58) and may accumulate
excessively in CF lung (59). In one model, heterozygous
SERCA2 knockout (SERCA2a1/2) mice showed substantially
enlarged infarction after cardiac ischemia (60). In addition,
they showed impaired postischemic myocardial relaxation and
reduced postischemic myocardial contractile function. These
animals had higher diastolic intracellular calcium without
oxidative stress and higher intracellular calcium after the
oxidative stress of reperfusion. The level of reactive oxygen
species production was not increased in the SERCA2 knock-
outs, but the level of dysfunction related to oxidative stress was
increased. Thus, there are precedents for substantial alter-
ations in cell survival and function in the heart with compara-
ble changes in SERCA2 expression to those seen in CF,
relative to non-CF, lung cells.
Intracellular calcium signaling depends upon SERCA activ-
ity. [Ca21]i can regulate a number of important functions
pertinent to airway epithelial cells, including mucus secretion,
ciliary contraction and motility, signal transduction, and cell
survival. Diminished SERCA activity in CF could dampen such
intracellular calcium signals and blunt adaptive chloride export.
Novel purinergic compounds in development for treatment of
CF are directed at stimulating intracellular calcium signals by
acting on extracellular ATP receptors that activate this process
(61). It was recently reported that ATP-induced increased short
circuit currents were lower in CF than non-CF small airway
epithelial cell cultures (62). Taken together, these data suggest
that SERCA inhibitor therapy would not likely be beneficial in
CF and that SERCA inhibition may worsen airway epithelial
cell survival under oxidative stress and decrease alternative
calcium-dependent chloride transport.
Hence, investigation of an alternate approach using
SERCA-stimulating interventions in clinically relevant models
of CF may be warranted by the present study.
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TABLE 2. SERCA2 KNOCKDOWN ENHANCES CELL DEATH
Control siRNA SERCA2 siRNA
Treatment Apoptosis (%) Necrosis (%) Apoptosis (%) Necrosis (%)
TNF 1 IL-1b (10 ng/ml for 18 h) 17.53 6 1.83 8.54 6 0.55 29.46 6 0.72* 9.53 6 0.39
H2O2 (500 mM for 18 h) 9.66 6 0.33 14.9 6 0.85 14.00 6 1.00* 28.33 6 1.66*
Definition of abbreviation: SERCA2 5 sarcoendoplasmic reticulum Ca21-ATPase; TNF 5 tumor necrosis factor.
* Significant difference from control siRNA-treated cells (P , 0.05). n 5 3, experiment repeated three times.
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